2008 PBL Cat_mech_r.qxd:PBL Catalog.mech 11/29/07 1:50 PM Page 20
Application Note
Plasma studies using the VeriKine
TM
Human Alpha Multi-Subtype Serum ELISA Kit (continued)
Figure 1: Human Plasma with Na-EDTA
Figure 2: Human Plasma with Na-Heparin
4
5
0nm
4
5
0nm
@ @
O
D
O
D
[IFN-α] (pg/ml) [IFN-α] (pg/ml)
Figure 1-2:IFN-α standard curves (12.5 pg/ml-500 pg/ml). Data above are plotted using linear values on a logarithmic scale.
Blue circle- Sample diluent, no Plasma
Black Diamond -25% Plasma in Sample diluent
Green Triangle-50% Plasma in Sample diluent
Red Square-75% Plasma in Sample diluent
Conclusions
• In human plasma samples spiked with exogenous IFN, the percent
• Using VeriKine
TM
Human IFN-α Multi-Subtype Serum Sample ELISA kit
difference between actual concentration of Human IFN-α spike and
(PBL product #41110), unknown concentrations of Human IFN-α in
concentration determined using ELISA product VeriKine
TM
Human
plasma can be quantified in plasma concentrations as high as 75% by
Interferon Alpha Multi-Subtype Serum kit (PBL product #41110) is
volume (25% sample diluent).
less than 10%.
• For higher % accuracy in samples with expected IFN concentrations in
• For accurate determination of concentration of Human IFN-α from
the lower end of the curve, we recommend a minimum dilution of a
plasma, the plasma sample must be diluted in the Sample Diluent
plasma sample into Sample Diluent of 1:2 (50% plasma final).
provided and its unknown concentration must be extrapolated from a
However, the results may vary slightly from lot to lot of IFN-α free
standard curve prepared in the same concentration of plasma.
Human Plasma.
• The plasma used to prepare the standard curve must contain an
• Due to increases in aggregates on Freeze/Thaw cycles, we do not
undetectable amount of Human IFN-α.
recommend repeated Freeze/Thaw cycles of plasma samples.
PBLInterferonSource Toll Free: 1 877- PBL-8881
20
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62